Literature DB >> 33506949

Quinacrine as a potential treatment for COVID-19 virus infection.

B Pineda1, V Pérez de la Cruz, R Hernández Pando, J Sotelo.   

Abstract

A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a current outbreak of infection termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 is currently a global pandemic that may cause close to half a billion deaths around the world. Until now, there is no effective treatment for COVID-19. Quinacrine (Qx) has been used since the 1930s as preventive antimalarial compound. It is a recognized small molecule inhibitor of RNA virus replication, with known anti-prion activity, and identified as a potent Ebola virus inhibitor both in vitro and in vivo. Recently, Qx has showed anti-SARS-CoV-2 activity. Herein, we review the potential mechanisms associated with quinacrine as an antiviral compound.

Entities:  

Year:  2021        PMID: 33506949     DOI: 10.26355/eurrev_202101_24428

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  3 in total

1.  Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters.

Authors:  Lucy Martinez-Guerrero; Xiaohong Zhang; Kimberley M Zorn; Sean Ekins; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2021-07-12       Impact factor: 4.402

2.  Identifying RBBP7 as a Promising Diagnostic Biomarker for BK Virus-Associated Nephropathy.

Authors:  Yicun Wang; Yuxuan Wang; Di Zhang; Hao Zhang; Wei Wang; Xiaopeng Hu
Journal:  J Immunol Res       Date:  2022-07-31       Impact factor: 4.493

3.  Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19.

Authors:  Benjamin Pineda
Journal:  Arch Med Res       Date:  2021-06-07       Impact factor: 2.235

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.